Spica Therapeutics has appointed Jeff Abbey as Chief Executive Officer (CEO). Abbey joins Spica with more than twenty years of executive management, strategic execution and fundraising experience across both public and private biopharmaceutical markets.
His appointment marks a pivotal inflection point as Spica accelerates its corporate strategy, expanding the deployment of its proprietary platform beyond oncology into broader, high-impact therapeutic areas, including fibroinflammatory conditions.
Jim Van heusden, Chairman of the Board, said: “Jeff has a stellar history of building international biotechnology companies and guiding them through complex clinical development paths. Jeff’s combination of operational expertise and fundraising success makes him uniquely suited to lead Spica as we scale our computational platform and advance our pipeline to resolve chronic disease.”
Abbey most recently served as CEO of RNatives, an RNA-based gene-regulating therapeutics company, where he has transitioned to Chairman of the Board. Prior to that, he was Chief Operating Officer and Chief Business Officer at ImmunOs Therapeutics, where he led operations and corporate development. Earlier in his career, Abbey spent over eight years as CEO of Argos Therapeutics, leading the company’s evolution from an early-stage venture into a publicly listed NASDAQ company.
Abbey commented: “While the industry has historically struggled with broad, non-specific myeloid treatments that cause systemic toxicities, Spica has unlocked true cellular precision. I look forward to working closely with our exceptional scientific team, board, and investors.”
Debbie Dumont, co-founder and Managing Partner at Bioqube Ventures and Spica Board Member, added: “With Jeff at the helm, the company gains a proven, international leader capable of converting our unique insights into macrophage biology into a robust pipeline of high-value clinical assets that redefine therapeutic paradigms.”